Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

David Lee

Sports Medicine Saint Louis, MO Medical Doctor

NPI 1114458023 CMS profile 7552822

1034 S Brentwood Blvd Ste 1120, Ste 1120, Saint Louis, MO 63117

Open in the dashboard

General payments

$1,425

69 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Lee of Saint Louis, MO is reported in the CMS Open Payments database as having received $1,425 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $214 10
2024 General $494 24
2023 General $717 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Lee
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to David Lee were reported at $214. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year David Lee Sports Medicine median Middle half National median
2019 $0 $119 $35–$362 $163
2020 $0 $77 $24–$275 $114
2021 $0 $104 $28–$340 $132
2022 $0 $94 $31–$272 $149
2023 $717 $91 $34–$271 $160
2024 $494 $126 $38–$294 $164
2025 $214 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Boston Scientific Corporation $278 8 payments
  2. Novartis Pharmaceuticals Corporation $233 12 payments
  3. Kiniksa Pharmaceuticals, Ltd. $125 5 payments
  4. Merck Sharp & Dohme Corporation $105 6 payments
  5. Amgen Inc. $94 5 payments
  6. Kiniksa Pharmaceuticals International, plc $90 4 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $84 5 payments
  8. AstraZeneca Pharmaceuticals LP $64 4 payments
  9. Impulse Dynamics (USA) Inc. $60 3 payments
  10. Pfizer Inc. $58 3 payments
  11. Other $234 14 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,425 69 payments
Products named General payments · program years 2023–2025
  1. WATCHMAN Access System $254 7 payments
  2. LEQVIO $233 12 payments
  3. Arcalyst $215 9 payments
  4. ENTRESTO $134 7 payments
  5. VERQUVO Cardiovascular $118 7 payments
  6. LifeVest $84 5 payments
  7. Repatha $79 4 payments
  8. VERQUVO Cardiovascular $74 4 payments
  9. OPTIMIZER Cardiovascular Device $60 3 payments
  10. OPTIMIZER Cardiovascular Device $60 3 payments
  11. Other $528 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

1,141

Median for Family Practice: 1,826

Drug cost

$55,258

Median for Family Practice: $120,094

Branded share of claims

9.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 21 $27,019
Ozempic Semaglutide Brand 20 $18,960
Lidocaine Generic 13 $959
Gabapentin Generic 54 $689
Atorvastatin Calcium Generic 89 $681
Albuterol Sulfate Hfa Albuterol Sulfate Brand 27 $648
Duloxetine Hcl Generic 13 $500
Lisinopril Generic 63 $375
Amlodipine Besylate Generic 79 $365
Ropinirole Hcl Generic 11 $358

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$21,138

Of which drugs: $965

Medicare patients

103

Average age 70

Services billed

484

60 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 62%
Diabetes 28%
Ischemic heart disease 28%
Chronic kidney disease 24%
Depression 22%
Heart failure 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 178 $134

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $90
$90 — —
Repatha
  • Amgen Inc. $39
$39 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $37
$37 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $19
$19 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $19
$19 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record